BioRestorative surges ~30% on upcoming US patent linked to metabolic ThermoStem program
cagkansayin
- BioRestorative Therapies (NASDAQ:BRTX) said the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for a patent application related to its metabolic ThermoStem program.
- The upcoming patent would be the third U.S. patent to issue from the company's ThermoStem family aimed at obesity and metabolic disorders, including type 2 diabetes, BioRestorative added.
- The company noted that claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes which have been derived from human brown adipose-derived stem cells.
- "Additionally, it enhances our ability to engage with the strategic community on collaborative and partnering opportunities," said CEO Lance Alstodt.
- BRTX +32.26% to $3.69 premarket March 2